Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IM-1021

Antibody-drug conjugate · Cytotoxic, directed at receptor tyrosine kinase-like orphan receptor 1 (ROR1) · developed by Immunome

Phase 1 Most advanced trial
IMNM Developer
1 Registered trials

What is IM-1021?

IM-1021 is an antibody-drug conjugate in which an IgG1 monoclonal antibody binds ROR1 on tumor cells and delivers the topoisomerase I inhibitor HC74 via a cleavable linker. After internalization, released HC74 inhibits DNA replication, causing cell cycle arrest and apoptosis, and it can also act on neighboring tumor cells. It is being studied in solid and hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
receptor tyrosine kinase-like orphan receptor 1 (ROR1), topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis, bystander killing of neighboring tumor cells
Therapy area
Oncology
Developer
Immunome, Inc. (IMNM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06823167 Phase 1 Solid Malignancies Recruiting IMNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hematologic MalignanciesSolid Malignancies

Other drugs acting on ROR1

More from Immunome

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.

Follow IMNM, the company behind IM-1021

See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMNM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.